Otsuka Holdings Co. Ltd.

04/13/2021 | Press release | Distributed by Public on 04/13/2021 00:00

Decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia